Status:
RECRUITING
Protective Effect of Sivelestat Against Negative Pulmonary Function and Organ Dysfunction After Cardiovascular Surgery (PANDA VI)
Lead Sponsor:
Nanjing Medical University
Collaborating Sponsors:
The First Affiliated Hospital with Nanjing Medical University
Beijing Anzhen Hospital
Conditions:
Aortic Dissection
Systemic Inflammatory Response Syndrome
Eligibility:
All Genders
18-90 years
Phase:
NA
Brief Summary
Systemic inflammatory response syndrome (SIRS) and multiple organ dysfunction syndrome (MODS) are the major causes of death in patients with cardiovascular diseases. Therefore, the prevention of SIRS ...
Eligibility Criteria
Inclusion
- The patients are conformed to 2010 ACC/AHA guidelines for the diagnosis and treatment of thoracic aortic disease (TAD) within two weeks of onset;
- Patients with type A acute aortic syndrome confirmed clinically and radiologically and planning to undergo emergency surgery were enrolled.
- The patients' age between 18 \~90 years old.
- Agree to participate in the study and sign the informed consent.
Exclusion
- Patients allergic to sivelestat sodium;
- Lactating women and pregnant women;
- Patients with mental diseases, drug and alcohol dependence;
- Refuse to participate in this study and refuse to sign the informed consent.
Key Trial Info
Start Date :
July 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT06195267
Start Date
July 1 2024
End Date
December 31 2025
Last Update
November 22 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Anzhen Hospital
Beijing, China
2
The First Affiliated Hospital of Nanjing Medical University and Jiang ye-fan
Nanjing, China